FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 409 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... May 15, 2019 ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Population-based lung cancer screening can reduce mortality in people who have... March 27, 2026 Load more HOT NEWS ESMO Publishes First Guidance on the Safe Use of Large Language... ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press... Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...
